Key result
High-risk non-cardiac surgery 1-12 months after DES implantation was associated with increased 30-day major cardiovascular events compared to low-risk surgery.
Why the study?
Does the ESC/ESA risk model accurately predict 30-day perioperative cardiac risk in patients undergoing non-cardiac surgery 1-12 months after DES implantation?
Does the ESC/ESA risk model accurately predict 30-day perioperative cardiac risk in patients undergoing non-cardiac surgery 1-12 months after DES implantation?
Answers are grounded in this paper and cite their sources.
The ESC/ESA non-cardiac surgery risk score provides a simple and robust estimation of 30-day perioperative cardiac risk in patients undergoing non-cardiac surgery 1-12 months after DES implantation.
This editorial refers to ‘Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation’, by K. Norderud et al., on page 22. Perioperative cardiovascular events following non-cardiac surgery have been estimated to occur in 3% of hospital admissions for surgery.1 With a world-wide volume of major surgical procedures estimated at greater than 300 million per annum in 2012,2 these events pose a significant global health care burden. Determining patients’ cardiovascular risk in advance of their operation is a key step in preoperative assessment. A number of risk stratification tools have been developed based on type of surgery3 and patient factors4,5 (Figure 1). Three commonly used preoperative risk stratification tools. The Revised Cardiac Risk Index and the ACS NSQIP surgical risk calculator utilize a combination of type of surgery and patient factors, while the ESC/ESA risk score utilizes only the former. aLee et al.4; bKristensen et al.6; cBilimoria et al.,5 available at https://riskcalculator.facs.org/RiskCalculator/. ACS NSQIP, American College of Surgeons National Surgical Quality Improvement Program; ASA, American Society of Anasthaesiologists; BMI, body mass index; CAS, carotid artery stenting; CEA, carotid endarterectomy; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESA, European Society of Anaesthesiology; ESC, European Society of Cardiology; IHD, ischaemic heart disease; TIA, transient ischaemic attack. The simplest of these models, published jointly by the European Society of Cardiology and European Society of Anaesthesiology (ESC/ESA), provides a 30-day estimate of cardiac death and myocardial infarction after non-cardiac surgery according to the type of procedure.6 These estimates are adapted from the Surgical Mortality Probability Model, in turn derived from a cohort of patients undergoing non-cardiac surgery between 2005 and 2007.3 Estimated risk is based solely on the type of surgery; no other clinical factors are taken into consideration. Procedures are classified as low risk (<1%, e.g. minor orthopaedic surgery), intermediate risk (1–5%, e.g. major orthopaedic surgery), and high risk (>5%, e.g. major vascular repair). In the absence of randomized controlled trials, external validation of these scores in real-world registries provides valuable confirmation of their clinical applicability. Patients who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents (DES) represent a population at potentially higher risk of perioperative cardiac events.7 Delayed endothelialization, premature discontinuation of antiplatelet therapy, and the proinflammatory, prothombotic milieu, and physiological stresses associated with surgery are all thought to contribute to the excess of perioperative mortality and myocardial infarction observed in this cohort. Importantly, this risk is greatest when non-cardiac surgery is performed early after PCI,7,8 with improved clinical outcomes when surgery is deferred for at least 6–12 months.9 It is against this background that Norderud et al. have examined the validity of the ESC/ESA risk model. Using retrospective, observational linkage data from Danish national registries, the authors compared clinical outcomes for 4046 patients who underwent non-cardiac surgery 1–12 months after PCI with DES. Perioperative risk was estimated according to the ESC/ESA model.10 The median age was 68 years; more than two-thirds of the patients were male. First-generation DES were used in the majority of patients (60%). One in four patients underwent non-cardiac surgery for an acute indication and the median time to surgery was 175 days (interquartile range 100–266). The recommended duration of dual antiplatelet therapy following DES implantation in Denmark during the study period was 12 months. Surgery was stratified into low (n = 2945), intermediate (n = 1014), or high-risk (n = 87) groups according to the ESC/ESA model. Patients undergoing diagnostic endoscopic procedures or closed orthopaedic repositions were excluded. Two composite outcomes were examined: cardiac death and myocardial infarction (MACE), and all-cause mortality and myocardial infarction, occurring within 30 days post-procedure. In general, the ESC/ESA model performed well. At 30 days, major adverse cardiac events (MACE) rates were 0.6%, 1.2%, and 3.4% for low, intermediate, and high-risk surgery, respectively [unadjusted odds ratio (OR) 1.9 95% confidence interval (CI) 0.9–4.1 for intermediate risk and 5.8 (95% CI 1.7–20.1) for high risk], similar to those predicted by the model (<1%, 1–5%, and >5%). The combined endpoint of all-cause mortality and myocardial infarction demonstrated a similar trend across the risk groups (1.5%, 4.6%, and 14.9%) [unadjusted OR 3.1 (95% CI 2.1–4.7) for intermediate risk and 11.3 (95% CI 5.9–21.9) for high risk], albeit with a notable increase in hazard, presumably driven by non-cardiac death. In a more detailed examination of patient and surgical factors, acute coronary syndrome as an indication for the index PCI was associated with an increased risk of MACE, while increasing age, female gender, presence of peripheral arterial disease, and an acute indication for surgery were all associated with a greater risk of all-cause mortality and myocardial infarction. Only the ESC/ESA model and renal dysfunction predicted both composite endpoints. In contrast to previous data,7,8,11 timing of surgery did not appear to be associated with 30-day perioperative risk. However, it should be highlighted that the authors excluded those at greatest risk (i.e. surgery within 30 days of PCI). The authors are to be commended for this analysis, which provides valuable external validation of the easily applied ESC/ESA non-cardiac surgery risk score in a large cohort. It is, however, worth highlighting several potential limitations. The authors, and others, have previously demonstrated that patients undergoing non-cardiac surgery within 12 months of DES implantation are at increased risk of perioperative cardiac events.8 Although there was an increase in endpoints across risk groups that was consistent with the ESC/ESA risk model, rates of MACE were lower than predicted. Exclusion of patients who had undergone surgery within 30 days of PCI may have contributed to the discrepancy in observed event rates. Indeed, the majority of MACE in the cohort (77 events for ≤1 month vs. 31 events for >1–12 months)8 was excluded in the current study, arguably introducing a source of bias and restricting the applicability of the analysis. Other potential explanations include the confounding associated with a retrospective registry-based design and differences in the definition of surgical procedures across registries. Previous observational studies have reported rates of major non-cardiac surgery within the 12 months following PCI of >4%.12 In the current study, 21% of all patients who had undergone PCI with a DES underwent non-cardiac surgery within 12 months. This discrepancy likely reflects inclusion of frequently performed, low-risk procedures such as endoscopy involving biopsy or polypectomy. Finally, the authors describe baseline antiplatelet and anticoagulant use, but detailed periprocedural changes to antiplatelet regimes and the associated influence on clinical outcomes were not available. Although not specifically addressed by the current work, the continuing uncertainty around the perioperative management of antiplatelet therapy justifies discussion. Premature discontinuation of antiplatelet therapy following PCI is associated with an increased risk of death and myocardial infarction in the general population as well as in non-cardiac surgery.13 Conversely, continuing antiplatelet therapy is associated with a small but incremental increase in perioperative bleeding.14 Until further data are available, the risks of antiplatelet cessation must be carefully balanced against the risk of periprocedural bleeding on an individual basis. In conclusion, Norderud et al. have demonstrated that the ESC/ESA risk model affords a simple and robust estimation of perioperative cardiac risk in patients undergoing non-cardiac surgery within 1–12 months following DES implantation. These data provide another step forward in the use of preoperative risk stratification tools. The challenge now is to develop evidence-based therapeutic strategies to reduce perioperative risk. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Bing et al. (2018) conducted an editorial in Non-cardiac surgery after coronary drug-eluting stent implantation (n=4,046). High-risk non-cardiac surgery (ESC/ESA model) vs. Low-risk non-cardiac surgery was evaluated on Cardiac death and myocardial infarction (MACE) at 30 days (OR 5.8, 95% CI 1.7-20.1). High-risk non-cardiac surgery 1-12 months after DES implantation was associated with increased 30-day major cardiovascular events compared to low-risk surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: